News
-
US-based biopharm Revagenix announced that it has initiated a Phase 1 trial of Rev-56, which it describes as an “inhaled, anti-pseudomonal therapy for non-cystic fibrosis bronchiectasis (NCFB).” The first part of the study will evaluate… Read more . . .
-
According to Cipla, the FDA has approved the company’s ANDA for 100/50 mcg, 250/50 mcg, and 500/50 mcg strengths of its generic version of Advair Diskus fluticasone propionate / salmeterol DPI for the treatment of… Read more . . .
-
According to Cessatech, the EMA’s Committee for Medicinal Products for Human Use has adopted a negative opinion regarding Proveca’s pediatric-use marketing authorization (PUMA) of KemSu (CT001) sufentanil / ketamine nasal spray for the treatment of… Read more . . .
-
According to Aptar Pharma, parent company of OINDP-focused CRO Nanopharm, the UK Medicines and Healthcare Products Regulatory Agency has completed an inspection of Nanopharm’s facility in Cwmbran, Wales and has certified the location as GMP compliant.… Read more . . .
-
According to AstraZeneca, the Australian Therapeutic Goods Administration has approved a reformulated Breztri (Trixeo) Aerosphere budesonide / glycopyrronium / formoterol fumarate MDI with Solstice‘s Solstice Air HFO-1234ze as the propellant. Breztri is approved in Australia for the treatment of… Read more . . .
-
Both Chiesi and the UK’s Medicines and Healthcare products Regulatory Agency have announced the MHRA’s approval of a reformulated Clenil Modulite beclometasone MDI for the treatment of asthma, marking the first approval of an MDI using Orbia‘s HFA 152a as… Read more . . .
-
According to Glenmark, the FDA has approved the company’s sNDA to extend the use of Ryaltris olopatadine / mometasone nasal spray for the treatment of seasonal allergic rhinitis to patients aged 6 -12. Ryaltris was… Read more . . .
-
Eli Lilly and Company has agreed to pay approximately $2.8 billion up front and up to an additional $1 billion in milestone payments for pyschedelics developer AtaiBeckley, the companies said. AtaiBeckley’s lead candidate is BPL-003… Read more . . .
-
Dutch CDMO Basic Pharma announced that German investment firm SHS Capital has acquired a majority stake in the company, with the investment expected to support additional manufacturing capacity. The announcement highlights Basic Pharma’s development and… Read more . . .
-
According to Texas-based CDMO Matica Biotechnology, the company will provide development and manufacturing services to vaccine developer VaxDome, also based in Texas, to advance a VaxDome intranasal antiviral / vaccine candidate into clinical trials. Matica… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
May 30-June 2: ISAM Congress 2027, Dublin, Ireland
June 23: SMI London, London, UK

